You are here
April 2019 news from faculty and staff of the College of Pharmacy Duluth.
Heather Blue, assistant professor, has been nominated Duluth Teacher of the Class of 2019.
Jacob T. Brown, assistant professor, J. R. Bishop, K. Sangkuhl, E. Nurmi, D. Muller, J. Dinh, A. Gaedigk, T. Klein, K. Caudle, J. McCracken, J. de Leon, and J. S. Leeder had their article, “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy,” published in Clinical Pharmacology & Therapeutics. 2019 Feb 22. doi: 10.1002/cpt.1409. [Epub ahead of print]
Keri Hager, associate professor, received an academic scholarship from the Institute for Healthcare Improvement to cover 50% of the cost to attend its Leadership and Organizing for Change course. Her project for the course will focus on improving care for people with opioid use disorder in the Duluth area.
Hager, along with UMD colleagues Julie Slowiak and Rachel Gilbertson, presented "Trouble sleeping? What can you do?" at the March 21, 2019, UMD Wellness Collaborative meeting. Resources can be found here.
Amanda Klein, assistant professor, participated in the March 15, 2019 National Institute of Neurological Disorders and Stroke Special Emphasis Panel at the Translational Neural, Brain, and Pain treatment Device Review Meeting ZNS1 SRB-S (01) in Washington, D.C.
Venkatram Mereddy, professor, is the 2018–19 recipient of the University of Minnesota Duluth Outstanding Graduate Faculty Advisor Award, which honors one faculty member from UMD’s Graduate School who has demonstrated outstanding service to the University through advising and mentoring.
Olihe Okoro, assistant professor, presented at the Annual Conference of the Center for Healthy African American Men through Partnerships (CHAAMPS) held at the University of Minnesota on February 28-March 1, 2019:
Invited speaker: "Leveraging the Influence of Women to Address Cancer Disparities in African American Men"
Poster: Okoro, G. Simmons, S. Witherspoon, and C. Nelson presented a poster "Engaging Women in Community-based Education to Address Health Disparities in African-American Men."
Okoro presented a mini workshop on the "Impact of Microaggressions on Health of Black Women: Becoming Aware & Taking Action" for Community Action Duluth staff on March 11, 2019.
Okoro and S. O. Whitson had their article, “Sexual health, HIV care and pre-exposure prophylaxis in the African immigrant population: A needs assessment,” published in The Journal of Immigrant and Minority Health. 2019, pp.1-11.
Laura Palombi, assistant professor, has been recognized by the Minnesota Prevention Resource Center (MPRC) as a Prevention Champion for her work in supporting rural Minnesota communities with the opioid crisis.
Palombi is the recipient of the St. Louis County 2019 Public Health Achievement Award for her leadership, collaboration, advocacy and contributions to the public health system.
Palombi, Blue, and Brandon Hankey presented "Responding to the Opioid Crisis: Using Valuable Tools" at the Arrowhead EMS Annual Conference on January 27, 2019, in Duluth.
Palombi presented "Community Based Solutions to the Opioid Crisis in Rural Minnesota" for the Supplemental Nutrition Assistance Program Education Team Seminar on February 15, 2019.
Palombi, Marcia Gurno, and Elisabeth Bilden presented "Naloxone: A Critical Tool to Fight the Opioid Crisis" for University of Minnesota Duluth Health Services Naloxone Training on February 21, 2019.
Palombi, Marcia Gurno, and Elisabeth Bilden presented "Naloxone to Reverse Opioid Overdose" for Mesabi Range Community College Naloxone Training on February 26, 2019, in Virginia, Minn.
Palombi presented an AACP Substance Use Disorder SIG Webinar titled "Strategic Engagement in Substance Use Prevention and Intervention: Utilizing Opportunities for Community-Engaged Research" on March 4, 2019.
Palombi, M. Olivarez, L. Bennett, and A. N. Hawthorne had their article, “Community forums to address the opioid crisis in rural Minnesota: An effective grassroots approach to continued community engagement,” published in Substance Abuse. 2019. doi: 10.1177/1178221819827595. [Epub ahead of print]
David D. Stenehjem, associate professor, T. H. Au, S. Ngorsuraches, J. Ma, H. Bauer, T. Wanishayakorn, R. S. Nelson, C. M. Pfeiffer, J. Schwartz, B. Korytowsky, G. Oderda, and D. I. Brixner had their article, “Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center,” published in Melanoma Research. 2019 Jan 25. doi: 10.1097/CMR.0000000000000572. [Epub ahead of print]
Stenehjem, A. W. Hahn, D. M. Gill, D. Albertson, B. Gowrishankar, J. Merriman, A. M. Agarwal, V. Thodima, E. B. Harrington, T. H. Au, B. L. Maughan, J. Houldsworth, S. K. Pal, and N. Agarwal had their article, “Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma,” published in PLOS ONE. 2019 Jan 25;14(1):e0210415. doi: 10.1371/journal.pone.0210415. eCollection 2019.
A. W. Hahn, Stenehjem, A. B. Alex, D. M. Gill, H. H. Cheng, E. R. Kessler, N. Chittoria, P. Twardowski, U. Vaishampayan, and N. Agarwal had their article, “Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer,” published in Urologic Oncology. 2019 Feb 13. pii: S1078-1439(19)30050-X. doi: 10.1016/j.urolonc.2019.01.029. Co-first author with equal contribution. [Epub ahead of print]
A. W. Hahn, Stenehjem, R. Nussenzveig, E. Carroll, E. Bailey, J. Batten, B. L. Maughan, and N. Agarwal had their article, “Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time,” published in Cancer Treatment and Research Communications. 2019 Feb 6;19:100120. doi: 10.1016/j.ctarc.2019.100120. Co-first author with equal contribution. [Epub ahead of print]
Conference Proceeding (Abstract and Poster): Stenehjem, I. Santi, K. Gupte-Singh, J. R. Penrod, and M. Venkatachalam. “Estimated costs of grade 3/4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC)” in the CheckMate 227 (CM-227) trial. (ASCO-SITC Clinical Immuno-Oncology Symposium, February 28, 2019, San Francisco, Cailf., U.S.A.)